BF Biosciences Ltd

BF Biosciences Ltd maintains a debt-to-equity ratio of 0.94, indicating a relatively balanced capital structure with a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 1.17, suggesting it has sufficient short-term assets to cover its short-term liabilities, but with limited excess liquidity. The company's free cash flow of 45.32 million PKR indicates a modest ability to fund operations and growth without external financing.

In terms of profitability, BF Biosciences Ltd reported a net income of 71.36 million PKR and an operating income of 129.25 million PKR. The return on equity (ROE) of 3.02% and return on assets (ROA) of 1.22% suggest that the company is generating relatively modest returns compared to industry benchmarks, which typically expect higher ROE and ROA for pharmaceutical firms.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher operational and market risks, particularly in the event of regional economic downturns or regulatory changes.

Looking ahead, the company's revenue growth trajectory is uncertain, with no specific guidance provided in the available data. However, the capital expenditure of -143.13 million PKR indicates a reduction in investment in physical assets, which may signal a strategic shift or financial constraints. The company's operating cash flow of 661.70 million PKR provides a buffer for ongoing operations and potential reinvestment.

The risk assessment highlights a key flag: the company's net cash position is negative after accounting for total debt, which could pose liquidity challenges if not managed effectively. The dilution risk is assessed as low, with no significant dilution expected in the near term, as the number of shares outstanding remains unchanged between basic and diluted shares.

Recent financial filings and disclosures indicate that the company has maintained a stable financial position, with no major events reported in the latest available data. The absence of significant changes in the capital structure or strategic direction suggests a conservative approach to business operations and financial management.

Revenue surged 102.2% year-over-year to PKR 5.8 billion, demonstrating strong top-line growth momentum.

Net income jumped 158.6% to PKR 447 million, significantly outpacing revenue growth and expanding profitability.

Free cash flow turned positive at PKR 311 million, reversing previous deficits and improving liquidity generation.

Cash conversion ratio of 9.27 is best-in-class compared to the pharmaceutical cohort median of 0.95.

Debt-to-equity ratio of 0.94 places the company in the bottom quartile of its pharmaceutical peer group.

The company faces high credit risk, signaling potential difficulties in meeting financial obligations or securing favorable financing.

Return on equity of 3.0% remains low, suggesting limited efficiency in generating profits from shareholder capital.

Revenue CAGR of -11.0% over four years indicates a long-term declining trend despite recent recovery.

Medium liquidity risk suggests potential challenges in meeting short-term financial obligations without significant asset liquidation.

Revenue PKR 1.62B, +118,4% YoY; Operating income +58,9% YoY.

• ▍Revenue PKR 1.62B, +118,4% YoY
• ▍Operating income +58,9% YoY
• ▍Net income +77,7% YoY
• ▍Free cash flow +46,6% YoY
• ▍Net margin 7.8%

Revenue PKR 1.50B; Operating income PKR 230.9M.

• ▍Revenue PKR 1.50B
• ▍Operating income PKR 230.9M
• ▍Net margin 8.3%

Revenue PKR 1.33B; Operating income PKR 193.9M.

• ▍Revenue PKR 1.33B
• ▍Operating income PKR 193.9M
• ▍Net margin 6.1%

Revenue PKR 5.84B, +59,5% YoY; Operating income +16,1% YoY.

• ▍Revenue PKR 5.84B, +59,5% YoY
• ▍Operating income +16,1% YoY
• ▍Net income +16,0% YoY
• ▍Free cash flow +11,8% YoY
• ▍Net margin 7.7%